Peroxisome proliferator-activated receptors (PPARs): Nuclear receptors at the crossroads between lipid metabolism and inflammation

Inflammation Research

Volumn 49, Issue 10, 2000, Pages 497-505

  Chinetti, G ^a   Fruchart, J C ^a   Staels, B ^a  

^a INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Fatty acids; Gene expression; Hypolipidemic drugs; Transcription factors

Indexed keywords

ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; CELL NUCLEUS RECEPTOR; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; LEUKOTRIENE B4; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROSTAGLANDIN J2; STAT PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA;

FATTY ACID OXIDATION; GENE ACTIVATION; GLUCOSE HOMEOSTASIS; IMMUNOMODULATION; INFLAMMATION; LIPID METABOLISM; LIPID STORAGE; LIPOPROTEIN METABOLISM; MACROPHAGE; MONOCYTE; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

EID: 0033793133     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000110050622     Document Type: Review

References (88)

1. The nuclear receptor superfamily: The second decade
2. Differential expression of peroxisome proliferator-activated receptors: Tissue distribution of PPARα, β and γ in the adult rat
3. Tissue distribution and quantification of the expression of mRNAs of Peroxisome Proliferator-Activated Receptors and Liver X Receptor a in humans
4. Member of peroxisome proliferator-activated receptor family of transcription factors is differentially expressed by oligodendrocytes
5. Differential expression of peroxisome proliferator-activated receptor-α, -β and -γ during rat embryonic development
6. The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation
7. Polarity and specific sequence requirements of peroxisome proliferator-activated receptor (PPAR)/retinoid X receptor heterodimer binding to DNA
8. Fibrates increase human Rev-erbα expression in liver via a novel peroxisome proliferator-activated receptor response element
9. Activation of peroxisome proliferator-activated receptors a and y induces apoptosis of human monocyte-derived macrophages
10. The peroxisome proliferator-activated receptor-α is a negative regulator of macrophage activation
11. Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators
12. Cross-talk between Janus Kinase-Signal Transducer Activator of Transcription (JAK-STAT) and peroxisome proliferator-activated receptor a (PPARα) signaling pathways
13. PPAR activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the AP-1 signaling pathway
14. A CBP integrator complexmediates transcriptional activation and AP-1 inhibition by nuclear receptors
15. PPARa activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells
16. Suppression of rat glutathione transferase P expression by peroxisome proliferators: Interaction between Jun and peroxisome proliferator-activated receptor a
17. PPARα negatively regulates the vascular wall inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1
18. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
19. mPPARγ2: Tissue-specific regulator of an adipocyte enhancer
20. Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonic mucosa
21. Expression of peroxisome proliferator-activated receptor α (PPARα) in primary cultures of human vascular endothelial cells
22. PPARα activation in human endothelial cells increases plasminogen activator inhibitor type-I expression
23. Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo
24. Peroxisome proliferator-activated-receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells
25. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL
26. Macrophages in human atheroma contain PPARgamma: Differentiation-dependent peroxisomal proliferator-activated receptor gamma (PPAR-gamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro
27. Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein
28. CLA-1/SR-BI is expressed in atheroselerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors
29. Down regulation of peroxisome proliferator-activated receptor y expression by inflammatory cytokines and its reversal by thiazolidinediones
30. Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15 lipoxygenase
31. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ
32. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ
33. The PPARα-leukotriene B4 pathway to inflammation control
34. Oxidized phospholipids activate PPARα in a phospholipase A2-dependant manner
35. 15-Deoxy-Δ12,14 prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
36. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation
37. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ
38. An antidiabetic thiazolidinedione is a high affinity ligand for Peroxisome Proliferator-Activated Receptor γ(PPARγ)
39. Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs
40. Requirements for triggering of adipocyte differentiation by glucocorticoids and indomethacin
41. Induction of peroxisomal beta-oxidation by nonsteroidal anti-inflammatory drugs
42. Induction of the cytochrome P450 I and IV families and peroxisomal proliferation in the liver of rats treated with benoxaprofen. Possible implications in its hepatotoxicity
43. Mechanism of action of fibrates on lipid and lipoprotein metabolism
44. Alterations in lipoprotein metabolism in PPARα-deficient mice
45. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha)
46. PPARα and PPARγ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene
47. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal Acyl Coenzyme A Oxidase
48. Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary machanism relative to fibrates
49. Coordinate regulation Of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators
50. Cloning of a rat adipocyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during preadipocyte differentiation
51. Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner
52. Acyl-CoA synthetase mRNA expression is controlled by fibric-acid derivatives, feeding and liver proliferation
53. Fatty acids activate transcription of the muscle carnitine palmitoyltransferase I gene in cardiac myocytes via the peroxisome proliferator-activated receptor alpha
54. Control of human muscle-type carnitine palmitoyltransferase I gene transcription by peroxisome proliferator-activated receptor
55. Negative regulation of Peroxisome Proliferator-activated Receptor γ gene expression contributes to the antiadipogenic effects of Tumor Necrosis Factor-α
56. The short- and long-term effects of tumor necrosis factor-alpha and BRL49653 on peroxisome proliferator-activated receptor (PPAR)gamma2 gene expression and other adipocyte genes
57. TNF-alpha downregulates the peroxisome proliferator activated receptor-alpha and the mRNAs encoding peroxisomal proteins in rat liver
58. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats
59. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
60. PPARγ in monocytes: Less pain, any gain?
61. Cyclopentenone prostaglandins suppress activation of microglia: Down-regulation of inducible nitrice-oxide synthase by 15-deoxy-Δ12,14-prostaglandin J2
62. Inhibition of IkappaB kinaso phosphorylation by 15-deoxy-Delta (12,14)-prostaglandin J(2) in activated murine macrophages
63. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase
64. Inhibition of inducible nitric oxyde synthase by peroxisome proliferator-activated receptor agonists: Correlation with induction of heme oxygenase 1
65. Atherosclerosis - An inflammatory disease
66. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol
67. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients
68. Anti-atheromatous effects of fenofibrate, are independent of its hypolipidemic effect in cholesterol-fed rabbits
69. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia
70. Thiazolidinediones inhibit the production of monocyte chemo-attractant protein-1 in cytokine-treated human vascular endothelial cells
71. Thiazolidinedione inhibits production of RANTES in a cytokine-treated human lung epithelial cell line
72. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction
73. Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: A new possible role of PPAR-gamma on vascular endothelial function
74. Troglitazone upregulates nitric oxyde synthesis in vascular smooth muscle cells
75. 2 gene in vascular smooth muscle cells by a nuclear factor kappaB and peroxisome proliferator -activated receptor-mediated process
76. Secretory phospholipase A2 and lipoprotein lipase enhance 15-lipoxygenase-induced enzymic and nonenzymic lipid peroxidation in low-density lipoproteins
77. Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function
78. Insulin resistance and thrombosis: A cardiologist's view
79. Fibrate-modulated expression of fibrinogen, plasminogen activator inhibitor-1 and apolipoprotein A-I in cultured cynomolgus monkey hepatocytes: Role of the peroxisome proliferator-activated receptor alpha
80. Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells
81. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia
82. Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidaemic patients
83. Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb
84. Peroxisome proliferators enhance cyclooxygenase-2 expression in epithelial cells
85. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice
86. Inflammatory alterations in mesenteric adipose tissue in Crohn's disease
87. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response